Back to Search
Start Over
Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy.
- Source :
-
International journal of molecular sciences [Int J Mol Sci] 2021 Nov 09; Vol. 22 (22). Date of Electronic Publication: 2021 Nov 09. - Publication Year :
- 2021
-
Abstract
- Cancer immunotherapy is becoming more important in the clinical setting, especially for cancers resistant to conventional chemotherapy, including targeted therapy. Chimeric antigen receptor (CAR)-T cell therapy, which uses patient's autologous T cells, combined with engineered T cell receptors, has shown remarkable results, with five US Food and Drug Administration (FDA) approvals to date. CAR-T cells have been very effective in hematologic malignancies, such as diffuse large B cell lymphoma (DLBCL), B cell acute lymphoblastic leukemia (B-ALL), and multiple myeloma (MM); however, its effectiveness in treating solid tumors has not been evaluated clearly. Therefore, many studies and clinical investigations are emerging to improve the CAR-T cell efficacy in solid tumors. The novel therapeutic approaches include modifying CARs in multiple ways or developing a combination therapy with immune checkpoint inhibitors and chemotherapies. In this review, we focus on the challenges and recent advancements in CAR-T cell therapy for solid tumors.
- Subjects :
- Humans
Lymphoma, Large B-Cell, Diffuse immunology
Lymphoma, Large B-Cell, Diffuse therapy
Multiple Myeloma immunology
Multiple Myeloma therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
Receptors, Antigen, T-Cell immunology
Immunotherapy trends
Immunotherapy, Adoptive trends
Receptors, Antigen, T-Cell therapeutic use
T-Lymphocytes immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1422-0067
- Volume :
- 22
- Issue :
- 22
- Database :
- MEDLINE
- Journal :
- International journal of molecular sciences
- Publication Type :
- Academic Journal
- Accession number :
- 34830003
- Full Text :
- https://doi.org/10.3390/ijms222212126